Treatment effect size of memantine therapy in Alzheimer disease and vascular dementia

Alzheimer Disease and Associated Disorders

Volumn 20, Issue 3, 2006, Pages 133-137

  Smith, Matthew ^a   Wells, Jennie ^b   Borrie, Michael ^b  

^a LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Alzheimer disease; Axura; Cohen's d; Dementia; Ebixa; Memantine; Mixed dementia; Namenda; Treatment effect size; Vascular dementia

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; MEMANTINE;

AGITATION; ALZHEIMER DISEASE; BEHAVIOR; CALCULATION; CAREGIVER; CLINICAL TRIAL; COCHRANE LIBRARY; COGNITION; CONFUSION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; EFFECT SIZE; FUNCTIONAL ASSESSMENT; HUMAN; MEDICAL LITERATURE; MEDLINE; MULTIINFARCT DEMENTIA; OUTCOME ASSESSMENT; PHYSICIAN; PRIORITY JOURNAL; PSYCHOLOGIC TEST; PSYCINFO; PUBLICATION; RATING SCALE; REVIEW; SEVERE IMPAIRMENT BATTERY; SIDE EFFECT; SYMPTOM; SYSTEMATIC REVIEW;

ALZHEIMER DISEASE; DEMENTIA, VASCULAR; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MEMANTINE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33747485966     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-200607000-00002     Document Type: Review

References (21)

1. Cohen J. Statistical Power Analysis for the Behavioural Sciences. 2 ed. New Jersey: Erlbaum; 1988.
2. Ditzler K. Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial. Arzneimittelforschung. 1991;41:773-780.
3. Gortelmeyer R, Erbler H. Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. Arzneimittelforschung. 1992;42:904-913.
4. Pantev M, Ritter R, Gortelmeyer R. Clinical and behavioural evaluation in long-term care patients with mild to moderate dementia under memantine treatment. Zeitschrift fuer Gerontopsychologie und Psychiatrie. 1993;6:103-117.
5. Orgogozo JM, Rigaud AS, Stoffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2004; DOI:1834-1839.
6. Wilcock G, Mobius HJ, Stoffler A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002;17:297-305.
7. Peskind ER, Potkin SG, Pomara N, et al. Memantine monotherapy is effective and safe fr the treatment of mild to moderate Alzheimer's disease: a randomized controlled trial. American Association for Geriatric Psychiatry 17th Annual Meeting, Baltimore, MD; 2004; February 21-24.
8. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment with moderate to severe Alzheimer's disease already receiving donepezil. A randomized control trial. J Am Med Assoc. 2004;291:317-324.
9. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. NEJM. 2003;348:1333-1341.
10. Winblad B, Poritis N. Memantine in severe dementia: results of the M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 1999;14:135-146.
11. Van der Kam P, Hoeksma BH. ADL and behaviour rating scales for the evaluation of nurses' workload in psychogeriatric nursing homes. Tijdschrift voor Gerontologie en Geriatrie. 1989;20:159-166.
12. Guy W. CGI: Clinical global impressions. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology Rev Edition. Rockville: National Institutes of Health; 1976:217-220.
13. Areosa Sastre A, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev. 2005;CD003154. Review.
14. Reisberg B, Schneider L, Doody R, et al. Clinical global measures of dementia: position paper from the International Working group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1997;11(Suppl 3):8-18.
15. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308-2314.
16. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;11:1356-1364.
17. Spiegel R, Brunner C, Ermini-Funfschilling D, et al. New Behavourial Assessment Scale for Geriatric Out and Inpatients: The NOSGER (Nurses Observational Scale for Geriatric Patients). J Am Geriatr Soc. 1991;39:339-347.
18. Gottfries CG, Brane G, Steen G. A new rating scale for dementia syndromes. Gerontology. 1982;28(Suppl 2):20-31.
19. Livingston G, Katona C. The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis. Int J Geriatr Psychiatry. 2004;19:919-925.
20. Rockwood K. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2004;75:677-685.
21. Rogers SL, Farlow MR, Doody RS, et al. The Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 1998;50:136-145.